Name:
Clorazepate
Type:
Benzodiazepine
AKA:
Tranxene
Clorazepate image
Synthetic substance, no natural derivative
IUPAC Logo
Clorazepate image
Clorazepate, a benzodiazepine, was first developed in the 1960s. It was introduced for its anxiolytic and sedative effects. The compound became a widely used medication for anxiety and other conditions. Clorazepate's introduction reflected advancements in benzodiazepine therapy, but its use has been associated with dependence and regulatory controls.
Synthetic Substances Image
Clorazepate is a benzodiazepine that produces sedation and reduces anxiety. It can cause drowsiness, decreased heart rate, and muscle relaxation. Short-term effects include anxiety reduction and improved sleep, while long-term use may lead to dependence, tolerance, and cognitive impairment. Overdose risks include severe sedation, respiratory depression, and potential death. Safe dosing requires careful medical oversight. Recent research emphasizes its benefits in anxiety treatment and the risks of long-term use.
N/A
A benzodiazepine used for anxiety with sedative effects. Long-term use can lead to dependence, cognitive impairment, and mood disturbances. Research highlights its impact on GABA receptors and risks of psychological dependence.
N/A
Clorazepate, a benzodiazepine, is used to treat anxiety, seizures, and alcohol withdrawal symptoms. Benzodiazepines have a long history of use in managing mental health conditions, reflecting evolving societal attitudes towards psychiatric treatment and pharmaceutical intervention. In modern culture, clorazepate and other benzodiazepines are both praised for their therapeutic benefits and criticized for their potential for dependence and abuse. Clorazepate's role in mental health treatment underscores broader conversations about the balance between effective medication and the risks of long-term use. Media discussions often highlight personal stories of dependence, contributing to ongoing debates about mental health care and the ethics of psychiatric medication.
N/A